<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39223836</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-6256</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>American journal of epidemiology</Title><ISOAbbreviation>Am J Epidemiol</ISOAbbreviation></Journal><ArticleTitle>A Systematic Approach to Evaluating Instrumental Variable Assumptions: Applied Example of Glucose-lowering Medications and Risk for Hospitalized Heart Failure in Older Adults.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">kwae329</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/aje/kwae329</ELocationID><Abstract><AbstractText>One obstacle to adopting instrumental variable (IV) methods in pharmacoepidemiology is their reliance on strong, unverifiable assumptions. We can falsify IV assumptions by leveraging the causal structure, which can strengthen or refute their plausibility and increase the validity of effect estimates. We illustrate a systematic approach to evaluate calendar time IV assumptions in estimating the known effect of thiazolidinediones on hospitalized heart failure. Using cohort entry time before and after 09/2010, when the U.S. Food and Drug Administration issued a safety communication as a proposed IV, we estimated IV and propensity score-weighted 2-year risk differences (RDs) using Medicare data (2008-2014). We (i) performed inequality tests, (ii) identified the negative control IV/outcome using causal assumptions, (iii) estimated RDs after narrowing the calendar time range and excluding patients likely associated with unmeasured confounding, (iv) derived bounds for RDs, and (v) estimated the proportion of compliers and their characteristics. The findings revealed that IV assumptions were violated and RDs were extreme, but the assumptions became more plausible upon narrowing the calendar time range and restricting the cohort by excluding prevalent heart failure (the strongest measured predictor of outcome). Systematically evaluating IV assumptions could help detect bias in IV estimators and increase their validity.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Htoo</LastName><ForeName>Phyo T</ForeName><Initials>PT</Initials><Identifier Source="ORCID">0000-0003-4742-8306</Identifier><AffiliationInfo><Affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Jessie K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gokhale</LastName><ForeName>Mugdha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global access and values, oncology, Pfizer, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pate</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>University of North Carolina, Epidemiology, Chapel Hill, North Carolina, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-9723-3876</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology, Department of Medicine, University of North Carolina at Chapel Hill (John Buse).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonsson-Funk</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stürmer</LastName><ForeName>Til</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9204-7177</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Epidemiol</MedlineTA><NlmUniqueID>7910653</NlmUniqueID><ISSNLinking>0002-9262</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">calendar time IV</Keyword><Keyword MajorTopicYN="N">dipeptidyl peptidase-4 inhibitors</Keyword><Keyword MajorTopicYN="N">drug safety</Keyword><Keyword MajorTopicYN="N">glucose-lowering medications</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">instrumental variable</Keyword><Keyword MajorTopicYN="N">older adults</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>1</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39223836</ArticleId><ArticleId IdType="doi">10.1093/aje/kwae329</ArticleId><ArticleId IdType="pii">7747526</ArticleId></ArticleIdList></PubmedData></PubmedArticle>